The virtual 34th International Papillomavirus Conference took place last week, from November 15-19. The conference’s theme this year was: ‘Research and education for HPV elimination’.
Jeanettes E-Poster ‘A Candidate Broadly Protective HPV-Vaccine Targeting the L2 Minor Protein Demonstrates Promising Results in a Clinical Phase I Trial’ was selected for the ‘Featured E-posters’ section (no. 97), as part of the conference.
“It was the first time I was attending the IPVC conference, and I was honored to get the opportunity to present my E-poster. It was a well-organised virtual conference, and I learn so much more within the field of HPV, all the challenges we are still facing, the impact of COVID-19, and how much we still need to learn.”
Current HPV vaccines are based on L1 proteins and protects against nine HPV types, this still leaves out a panel of other relevant HPV types unaddressed, in particular beta-HPV types involved in the development of non-melanoma skin cancer (NMSC). In seeking broader protection, 2A Pharma has recently completed a first-in-human study using the AAVLP vaccine carrier to target the more conserved HPV-L2 proteins.
The E-poster includes preliminary results of our first-in-human study using the AAVLP vaccine carrier to target the conserved HPV-L2 proteins.
The aim of the conference is to present the latest research results and share knowledge through workshops, lectures, and (poster) presentations on papillomavirus-related topics, with a particular emphasis on HPV elimination.
“My take-home message from the conference is that it requires all nationalities, all genders, all efforts in the battle against HPV. We have come far, but there is still a long way to go. The IPVC is an opportunity to get together across all differences, share new knowledge and science and it is essential for reaching our common goal – HPV elimination.”
The next edition will be held in Kyoto, Japan, from March 27-31 2023. Visit the website for additional details about IPVC.